Podcasts

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Camidge and O'Donnell discussed O’Donnell’s career, which has culminated in his role as director of Research Partnerships at Cancer Research Society.

Drs Nunnery and Iyengar discuss lifestyle and medical interventions pertinent to breast cancer survivorship.

Camidge and Alvarez discussed Alvarez's career path, which has spanned roles from homicide detective to trial lawyer specializing in tobacco litigation.

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

David Morris, MD, FACS, and Alan H. Bryce, MD, discuss the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Drs Park and Beckermann discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium.

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Drs Rotow and Dietrich discuss the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated NSCLC.

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Marina Baretti, MD, discussed the potential utilization of tissue-free ctDNA monitoring for early recurrence detection and treatment monitoring in CCA.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, discuss the importance of identifying genomic drivers and resistance patterns for therapy selection in GIST.